{"title":"Late-Onset Ocular Hypotensive Effect of Ripasudil on Primary Open-Angle Glaucoma.","authors":"Kei Sano, Ryo Terauchi, Kota Fukai, Shumpei Ogawa, Takahiko Noro, Masayuki Tatemichi, Tadashi Nakano","doi":"10.2147/OPTH.S482883","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We evaluated the late-onset ocular hypotensive effect of ripasudil after long-term administration in real-world clinical data and investigated its associated factors in primary open-angle glaucoma (POAG).</p><p><strong>Patients and methods: </strong>We reviewed the clinical patients with POAG who newly started ripasudil without changes of treatment. Enrolled eyes were assigned to two groups: positive group with the late-onset effect and negative group. Eyes that show the late-onset effect 6 months after starting ripasudil were defined as positive. Logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the late-onset effect.</p><p><strong>Results: </strong>We enrolled 74 eyes of 74 patients with POAG (age, 67.5 ± 10.9 years; mean deviation, -11.2 ± 5.9 dB) and followed them for 14.2 ± 5.0 months. Among them, 12 (16.2%) eyes were assigned to the positive group. Retinal nerve fiber layer (RNFL) thickness (73.4 ± 12.9 vs 64.0 ± 9.8 μm, <i>P</i> = 0.04) and primary IOP (18.8 ± 4.1 vs 15.8 ± 4.3 mmHg, <i>P</i> = 0.01) before starting ripasudil were higher in the positive group than in the negative group. The late-onset effect was associated with higher IOP (OR, 1.22; 1.01-1.48) and thicker RNFL (2.76; 1.15-6.63).</p><p><strong>Conclusion: </strong>Some patients with POAG showed the late-onset IOP-lowering effect of ripasudil, and its associated factors were higher IOP and thicker RNFL. The addition of ripasudil may offer potential benefits particularly for early-stage glaucoma with thicker RNFL.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"18 ","pages":"3905-3912"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681902/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S482883","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: We evaluated the late-onset ocular hypotensive effect of ripasudil after long-term administration in real-world clinical data and investigated its associated factors in primary open-angle glaucoma (POAG).
Patients and methods: We reviewed the clinical patients with POAG who newly started ripasudil without changes of treatment. Enrolled eyes were assigned to two groups: positive group with the late-onset effect and negative group. Eyes that show the late-onset effect 6 months after starting ripasudil were defined as positive. Logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the late-onset effect.
Results: We enrolled 74 eyes of 74 patients with POAG (age, 67.5 ± 10.9 years; mean deviation, -11.2 ± 5.9 dB) and followed them for 14.2 ± 5.0 months. Among them, 12 (16.2%) eyes were assigned to the positive group. Retinal nerve fiber layer (RNFL) thickness (73.4 ± 12.9 vs 64.0 ± 9.8 μm, P = 0.04) and primary IOP (18.8 ± 4.1 vs 15.8 ± 4.3 mmHg, P = 0.01) before starting ripasudil were higher in the positive group than in the negative group. The late-onset effect was associated with higher IOP (OR, 1.22; 1.01-1.48) and thicker RNFL (2.76; 1.15-6.63).
Conclusion: Some patients with POAG showed the late-onset IOP-lowering effect of ripasudil, and its associated factors were higher IOP and thicker RNFL. The addition of ripasudil may offer potential benefits particularly for early-stage glaucoma with thicker RNFL.
目的:评价利帕舒地尔长期给药后的迟发性降压效果,并探讨其在原发性开角型青光眼(POAG)中的相关因素。患者和方法:回顾了新开始使用利帕舒地而未改变治疗方法的POAG患者的临床情况。将入组的眼睛分为两组:具有迟发效应的阳性组和阴性组。开始使用利帕舒地尔6个月后出现迟发性效应的眼睛被定义为阳性。采用Logistic回归模型计算迟发效应的优势比(ORs)和95%置信区间(ci)。结果:74例POAG患者入组74只眼(年龄:67.5±10.9岁;平均偏差为-11.2±5.9 dB),随访14.2±5.0个月。阳性组12只(16.2%)眼。利帕舒地尔开始治疗前,阳性组视网膜神经纤维层(RNFL)厚度(73.4±12.9 vs 64.0±9.8 μm, P = 0.04)和原发性IOP(18.8±4.1 vs 15.8±4.3 mmHg, P = 0.01)均高于阴性组。迟发效应与较高的IOP相关(OR, 1.22;1.01-1.48)和较厚的RNFL (2.76;1.15 - -6.63)。结论:部分POAG患者出现利帕舒地尔的晚发性降眼压作用,其相关因素为较高的IOP和较厚的RNFL。利帕舒地尔的加入可能提供潜在的益处,特别是对于早期青光眼较厚的RNFL。